Fosun Forms $95 Million China CAR-T JV with Kite Pharma

Shanghai Fosun Pharma formed a JV with Santa Monica's Kite Pharma to develop Kite's CAR-T immuno-oncology drug in China. Axicabtagene ciloleucel (KTE-C19), has completed clinical development in the US and Europe to treat B-cell lymphomas. Fosun will pay $40 million to Kite upfront and as much as $35 million in milestones. It will also provide $20 million for China development costs. The JV will also have an option for additional Kite products, including two T cell receptor candidates. More details.... Stock Symbols: (SHA:600196; HK:02196) (NSDQ: KITE) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.